本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
The Lion-China Merchants Emerging Asia Select Index ETF is part of the Singapore Exchange-Shanghai Stock Exchange (SGX-SSE) ETF Product Link and aims to track the 50 largest and most tradable companies domiciled in Emerging Asia and listed in Emerging Asia countries or the US Exchanges, providing access to growth in these markets including India, Indonesia, Thailand and Malaysia. SINGAPORE, Nov. 25, 2024 /PRNewswire/ -- Lion Global Investors (LGI) and China Merchants Fund Management (CMF) today announced their collaboration to launch the Lion-China Merchants Emerging Asia Select Index ETF, the world's first emerging Asia ETF traded in SGD. This ETF is LGI's seventh ETF and marks CMF's first collaboration with an ETF issuer in Singapore. Providing investors easy access to emerging Asia economies The investment objective of the Lion-China Merchants Emerging Asia Select Index ETF seeks to replicate the performance of the iEdge Emerging Asia Select 50 Index by tracking the 50 largest and most tradable companies in four key emerging Asia markets - India, Malaysia, Indonesia and Thailand and providing access to growth in these countries. According to a June 2024 report by the World Economic Forum, India and Indonesia are emerging as important players in the regional economy and global value chains. With an expected GDP growth of 6.8% this year1, India is at the forefront of Asian growth and is poised to overtake Germany to become the world's third largest economy by 2030; while Indonesia's GDP currently contributes to 40% of ASEAN's GDP and the country is expected to double its GDP between 2022 and 20322. Malaysia's economy experienced a growth acceleration in the first half of 2024 underpinned by its strong trade performance and foreign direct investment3 while Thailand is expected to experience a tourism rebound and reach 41.6 million arrivals by 2025, back to its pre-pandemic levels for the first time since Covid4. The Lion-China Merchants Emerging Asia Select Index ETF counts index constituents such as Indonesia's Bank Central Asia and India's HDFC Bank and Thailand's PTT PCL* among its top constituents (as of October 31, 2024), with larger allocations to sectors like finance, technology and energy. The ETF may appeal to investors who are looking to gain access into these growing markets or sectors within India, Malaysia, Indonesia and Thailand. Kwok Keng Han, Chief Marketing Officer at Lion Global Investors: "While developed markets often take the Asian spotlight, we are now seeing notable focus on emerging Asia markets and are committed to providing an easier channel for clients to access these markets. The encouraging adoption we see from investors across our range of ETF offerings in the past year underlies the belief that investors see value in cost-efficient, well-designed strategies that combine the best elements of indexing with the potential to achieve better outcomes for well-diversified portfolios." Lion Global Investors' total ETF Assets under Management (AUM) reached the SGD 1 billion mark in 2024 and its ETF business has grown 37% year-to-date as of October 31, 2024. Riding on this growth momentum, the Lion-China Merchants Emerging Asia Select Index ETF will be Lion Global Investors' third ETF listing in 2024, bringing the total number of ETFs listed on the SGX to seven since entering the ETF space in 2017. With this new ETF, LGI will have the largest number of ETFs on the SGX. *All securities referenced above are not intended as recommendations to buy or sell. Robust capabilities, blended synergies With the robust expertise of Lion Global Investors and China Merchants Fund Management in their respective Singapore and China markets, the collaboration aims to drive growth for both companies while delivering value for investors in both markets. As the asset management arm of China Merchants Group, one of the largest state-owned enterprises in China with diverse business operations, China Merchants Fund Management offers clients investment strategies across mainland China, including mutual funds, pension funds, social security funds and QDII solutions, dedicated to the mission of 'creating more value for investors'. The company manages the largest CSI A500 ETF listed on the Shanghai Stock Exchange, which is tracking the CSI A500 Index with an AUM of RMB 13.6 billion as of November 15, 2024. Dr Xu Yong, General Manager, China Merchants Fund Management: "China Merchants Fund Management is pleased to partner with Lion Global Investors, one of Singapore's leading asset management companies, to provide innovative solutions and offerings to expand investor access to more markets. Through this collaboration, we will be able to offer a new allocation tool for domestic investors, providing scalable solutions and thereby enhancing our service to investors." As part of its involvement in the SGX-SSE ETF Product Link, China Merchants Fund Management will reciprocate with the listing of a feeder ETF for the Lion-China Merchants Emerging Asia Select Index ETF on the Shanghai Stock Exchange by March 2025. Initial Offering Period The Initial Offering Period (IOP) of the Lion-China Merchants Emerging Asia Select Index ETF is from November 25 to December 6, 2024. The issue price of each unit during the IOP is SGD 1.30 (or the approximate equivalent of USD 1). The ETF will list on the Singapore Stock Exchange (SGX) on December 11, 2024 and will be available in Singapore dollar under the SGX code EAA. During the IOP, investors may subscribe to the ETF through OCBC ATMs/internet banking/mobile banking and participating dealers including iFAST Financial Pte. Ltd., OCBC Securities Pte. Ltd., Phillip Securities Pte. Ltd., Maybank Securities and Tiger Brokers (Singapore) Pte. Ltd. 1World Economic Forum: June 24, 2024 www.weforum.org/stories/2024/06/why-asia-s-time-is-now-whats-fueling-asian-growth-and-what-does-it-mean-for-the-rest-of-the-world2 S&P Global Market Intelligence: February 20243 McKinsey Southeast Asia quarterly economic review: Q2 20244 Thailand Business News: August 3, 2024: Thailand's Tourist Arrivals Expected to Grow in 2024 and Fully Rebound by 2025 Disclaimer – Lion Global Investors Limited This advertisement or publication has not been reviewed by the Monetary Authority of Singapore. It is for information only, and is not a recommendation, offer or solicitation for the purchase or sale of any capital markets products or investments and does not have regard to your specific investment objectives, financial situation, tax position or needs. You should read the prospectus and Product Highlights Sheet of the Lion-China Merchants Emerging Asia Select Index ETF ("ETF"), which is available and may be obtained from Lion Global Investors Limited ("LGI") or any of the its distributors and appointed Participating Dealers ("PDs"), for further details including the risk factors and consider if the ETF is suitable for you and seek such advice from a financial adviser if necessary, before deciding whether to purchase units in the ETF. Investments in the ETF are not obligations of, deposits in, guaranteed or insured by LGI or any of its affiliates and are subject to investment risks including the possible loss of the principal amount invested. The performance of the ETF is not guaranteed and, the value of its units and the income accruing to the units, if any, may rise or fall. Past performance, payout yields and payments, as well as, any prediction, projection, or forecast are not necessarily indicative of the future or likely performance, payout yields and payments of the ETF. Any extraordinary performance may be due to exceptional circumstances which may not be sustainable. Dividend distributions, which may be either out of income and/or capital, are not guaranteed and subject to LGI's discretion. Any such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value of the ETF. Any references to specific securities are for illustration purposes and are not to be considered as recommendations to buy or sell the securities. It should not be assumed that investment in such specific securities will be profitable. There can be no assurance that any of the allocations or holdings presented will remain in the ETF at the time this information is presented. Any information (which includes opinions, estimates, graphs, charts, formulae or devices) is subject to change or correction at any time without notice and is not to be relied on as advice. You are advised to conduct your own independent assessment and investigation of the relevance, accuracy, adequacy and reliability of any information or contained herein and seek professional advice on them. No warranty is given and no liability is accepted for any loss arising directly or indirectly as a result of you acting on such information. The ETF may, where permitted by the prospectus, invest in financial derivative instruments for hedging purposes or for efficient portfolio management. The ETF's net asset value may have higher volatility as a result of its narrower investment focus on Emerging Asia countries, when compared to funds investing in developed markets. LGI, its related companies, their directors and/or employees may hold units of the ETF and be engaged in purchasing or selling units of the ETF for themselves or their clients. The units of the ETF are listed and traded on the Singapore Exchange Securities Trading Limited ("SGX-ST"), and may be traded at prices different from its net asset value, suspended from trading, or delisted. Such listing does not guarantee a liquid market for the units. You cannot purchase or redeem units in the ETF directly with the manager of the ETF, but you may, subject to specific conditions, do so on the SGX-ST or through the PDs. © Lion Global Investors Limited (UEN/ Registration No. 198601745D). All rights reserved. LGI is a Singapore incorporated company and is not related to any corporation or trading entity that is domiciled in Europe or the United States (other than entities owned by its holding companies). Disclaimer – Singapore Exchange Limited for iEdge Emerging Asia Select 50 Index The units of the Lion-China Merchants Emerging Asia Select Index ETF are not in any way sponsored, endorsed, sold or promoted by the Singapore Exchange Limited ("SGX") and/or its affiliates and SGX and/or its affiliates make no warranty or representation whatsoever, expressly or impliedly, either as to the results to be obtained from the use of the iEdge Emerging Asia Select 50 Index and/or the figure at which the iEdge Emerging Asia Select 50 Index stands at any particular time on any particular day or otherwise. The iEdge Emerging Asia Select 50 Index is administrated, calculated and published by SGX. SGX shall not be liable (whether in negligence or otherwise) to any person for any error in the Lion-China Merchants Emerging Asia Select Index ETF and the iEdge Emerging Asia Select 50 Index and shall not be under any obligation to advise any person of any error therein. Intellectual property rights in the iEdge Emerging Asia Select 50 Index vest in SGX. The iEdge Emerging Asia Select 50 Index is used by Lion Global Investors Limited under licence. Disclaimer – China Merchants Fund Management Company Limited The references to the company name and logo of China Merchants Fund Management Company Limited in this material do not constitute a guarantee by China Merchants Fund Management Company Limited of the authenticity, accuracy and completeness of the relevant content, nor do they constitute a judgment or guarantee by China Merchants Fund Management Company Limited of the investment value and performance of the Lion-China Merchants Emerging Asia Select Index ETF. China Merchants Fund Management Company Limited assumes no liability for this material or the investors' investment in the Lion-China Merchants Emerging Asia Select Index ETF. About Lion Global Investors Limited Lion Global Investors Limited (Co Reg No. 198601745D) is a part of Great Eastern Holdings and a member of the Oversea-Chinese Banking Corporation Limited (OCBC) Group. Established since 1986, it is a leading and one of the largest asset management companies in Southeast Asia, uniquely positioned to provide Asian equities and fixed income strategies and funds to both institutional and retail investors. As at 30 September 2024, our assets under management (AUM) stands at S$71.2 billion (US$55.6 billion). www.lionglobalinvestors.com About China Merchants Fund Management China Merchants Fund Management Co., Ltd. was established on December 27, 2002, with the approval of the China Securities Regulatory Commission (CSRC) as per Document No. 100 (2002). The registered capital stands at RMB 1.31 billion, with China Merchants Bank Co., Ltd. holding 55% and China Merchants Securities Co., Ltd. holding 45% of the company's total equity. Dedicated to the mission of 'creating more value for investors', China Merchants Fund upholds the core values of integrity, rationality, professionalism, collaboration, and growth. The company aims to establish itself as a leading brand with a competitive edge in China's asset management industry. As at 30 September 2024, China Merchants Fund Management Co., Ltd.'s mutual fund assets under management stands at RMB 890 billion. https://www.cmfchina.com
SINGAPORE, Nov. 25, 2024 /PRNewswire/ -- MediSun Energy, a company specializing in advanced osmotic (blue) energy technology, has successfully secured US$8.75 million in Seed financing round and established a strategic partnership with Southeast Asian venture capital firm Vynn Capital. The funding consists of US$5 million in venture debt and US$3.75 million in equity financing, bringing the company's valuation to US$44 million. In a joint statement, the parties said this marks one of the significant investments from Vynn Capital's Mobility and Supply Chain fund, backed by a number of Malaysian institutional investors and other regional limited partners. The funding round, led by Vynn Capital, attracted several new investors, including MOAJ Holding, a leading Saudi investment company; Frank Phuan; TNB Aura, a Singapore-based venture capital firm participating through its Scout Initiative; and Ciri Ventures, a climate tech-focused venture capital firm. On top of this, MOAJ Holding Co. has also committed to investing up to US$30 million into Medisun's Saudi Arabia business to form a local joint venture. The parties highlighted that this partnership aims to accelerate MediSun's expansion into the MENA region and further enhance its research and development capabilities. MediSun plans to establish two facilities: one dedicated to membrane production and the other for stack production. Dusun Kim, Founder & CEO of MediSun, stated: "At MediSun, we are dedicated to making the planet greener and better. Our zero-brine technology not only provides clean and green energy but also contributes to a more sustainable future. This partnership with Vynn Capital is a major milestone that will enable us to scale our operations and bring our innovative solutions to new markets. We are committed to leveraging this opportunity to further our mission of addressing the critical environmental challenges." Victor Chua, Founding & Managing Partner of Vynn Capital, added: "MediSun's solutions are crucial in solving water supply chain and scarcity issues while achieving net-zero carbon goals by reducing energy consumption. Over the medium term, we believe such technology can also be crucial for other industries, such as mobility and industrial sectors, that require innovation in energy management. This is especially important with the narrative of Malaysia and Southeast Asia playing a larger role in the renewable energy sector. Our investment in MediSun reflects our belief in the team's vision and our commitment to supporting groundbreaking technologies that have a positive impact on the environment and society." In addition to supporting MediSun's growth, Vynn Capital is actively exploring other opportunities and startups in key markets such as Singapore, Thailand, and Indonesia. With Southeast Asia's water technology market expected to grow significantly, this partnership positions both companies at the forefront of innovation and sustainability in the region. About MediSun Energy MediSun Energy is a technology-driven company dedicated to advancing clean and efficient energy solutions. Our innovative WEGen technology utilises osmotic power to enhance energy efficiency in water desalination and to generate renewable energy. Committed to a net-carbon neutral future, we strive to deliver practical, sustainable solutions that align with our vision of a world powered by clean and green energy. About Vynn Capital Vynn Capital is an industry focused early-stage venture capital firm founded with the objective of bridging the gap between traditional industries and the new economies through the development of technology. Vynn's investment philosophy revolves around the creation of synergistic value between portfolio companies and companies within the firm's ecosystem. For more information, visit www.medisun.energy or write to info@medisun.energy. You can also follow MediSun on LinkedIn.
香港2024年11月25日 /美通社/ -- 領先的內容社區及社交平台快手科技（「快手」或「公司」；港幣櫃台股份代號：01024 / 人民幣櫃台股份代號：81024）欣然宣佈，根據恒生指數公司2024年11月22日公佈的恒生指數系列檢討結果，快手將獲納入為恒生指數成份股，將於2024年12月9日生效。公司認爲，此次獲納入反映了資本市場對公司業務及發展前景的高度認可，標志著公司業務發展的重要裡程碑，並將有利於公司在資本市場交易流動性及估值的進一步提升。 此外，快手亦將被納入恒指 ESG 增強指數與恒指 ESG 增強精選指數，並將於2024年12月9日生效，彰顯了公司在履行社會責任與推動可持續發展方面的長期承諾。 恒生指數是受全球資本市場最廣泛引用的香港股票市場指標之一，優化後的恒生指數將加強主要行業組合在恒生指數中的覆蓋率，維持恒生指數作為香港股票市場整體表現的重要指標。恒生指數有限公司對入選的成份股有嚴謹的審批準則，會依據公司的市值和成交額、公司所屬行業界別在恒生指數所佔的比重，以及公司的財務表現等因素進行嚴格挑選。 關於快手 快手作為中國乃至全球領先的內容社區及社交平台，致力於成為全球最癡迷于為客戶創造價值的公司。作為一家以人工智能為核心驅動和技術依託的科技公司，快手專注於通過持續的技術創新和產品升級，不斷豐富服務和應用場景，為客戶創造價值。在快手，用戶通過短視頻和直播來記錄和分享他們的生活，發現所需，發揮所長。通過與內容創作者和企業緊密合作，快手提供的技術、產品和服務可滿足用戶的多元化的需求，包括娛樂、線上營銷服務、電商、本地生活、遊戲等。 前瞻性聲明 除過往事實的陳述外，本新聞稿載有若干前瞻性陳述。前瞻性陳述一般可透過所使用前瞻性詞彙識別，例如「或會」、「可能」、「可」、「可以」、「將」、「將會」、「預期」、「認為」、「繼續」、「估計」、「預計」、「預測」、「打算」、「計劃」、「尋求」或「時間表」。該等前瞻性陳述受風險、不確定因素及假設的影響，可能包括業務展望、財務表現預測、業務計劃預測、發展策略及對我們行業預期趨勢的預測。該等前瞻性陳述是根據本集團現有的資料，亦按本新聞稿刊發之時的展望為基準，在本新聞稿內載列。該等前瞻性陳述是根據若干預測、假設及前提作出，當中許多涉及主觀因素或不受我們控制。該等前瞻性陳述或會證明為不正確及可能不會在將來實現。該等前瞻性陳述涉及大量風險及不明朗因素。鑒於上述風險及不明朗因素，本新聞稿內所載列的前瞻性陳述不應視為董事會或本公司聲明該等計劃及目標將會實現，故投資者不應過於依賴該等陳述。除法律要求的情形外，我們並無責任公開發佈可能反映本新聞稿日期後發生的事件或情況或可能反映意料之外事件的該等前瞻性陳述的任何修訂。 投資者及媒體問詢 快手科技投資者關係郵箱：ir@kuaishou.com
ROCKVILLE, Md. and SUZHOU, China, Nov. 25, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has appointed Ms. Marina S. Bozilenko and Dr. Debra Yu as additional independent non-executive directors of the company with effect from November 25, 2024. "I would like to extend a warm welcome to Ms. Marina S. Bozilenko and Dr. Debra Yu, who are joining Ascentage Pharma as independent non-executive directors," said Dr. Dajun Yang, Chairman & CEO of Ascentage Pharma. "Both Ms. Bozilenko and Dr. Yu are accomplished industry veterans possessing a wealth of experience in the finance, investment, business development, and strategic management in the global biopharmaceutical sector. Ascentage Pharma is currently at a crucial stage of its development where we are making further strides with our global innovation strategy. We believe these two distinguished new members of our Board bring with them the invaluable insights and strategic acumen that will help propel the company into its next phase of growth." Ms. Marina S. Bozilenko is currently the President, CEO and a Director at Biothea Pharma, and an independent director at Talphera, Inc. (NASDAQ: TLPH). Previously, Ms. Bozilenko served as a Managing Director of William Blair & Co. LLC, a Senior Managing Director at Bear, Stearns & Co., Inc., and as a Managing Director at Banc of America Securities LLC. Before that, Ms. Bozilenko held various positions at Vector Securities International, Prudential Vector Healthcare Group, and Kidd & Co. LLC. Additionally, Ms. Bozilenko served as Directors at Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) and SynAct Pharma AB (Nasdaq Stockholm: SYNACT). Ms. Bozilenko received a bachelor's degree in biochemistry and master's degree in social science from the University of Chicago. Ms. Debra Yu. MD, is currently the Chief Operating Officer and a partner at Panacea Venture, a board member at MeiraGTx Holdings PLC (NASDAQ: MGTX), and an independent non-executive director of JW (Cayman) Therapeutics Co. Ltd (2126. HK). Previously, she served as the Chief Strategy Officer and President at LianBio (NASDAQ: LIAN). Prior to that, she was the Managing Director and head of cross border healthcare investment banking at China Renaissance Securities (U.S.) and the Managing Director of Labrador Advisors, LLC, where she advised numerous cross-border partnerships and licensing transactions. Earlier, she was the Vice President of Strategy at WuXi AppTec; a Senior Director and a leader of the venture capital team and the Worldwide Business Development organization at Pfizer. For many years, Dr. Yu has been a venture capitalist based in the San Francisco Bay Area where she served as a general partner of Delphi Ventures and the Managing Director of Bay City Capital. Dr. Yu has also held positions at McKinsey & Co. and Morgan Stanley. Dr. Yu received a bachelor's degree with high honors in molecular biology from Princeton University and a Doctor of Medicine degree from Harvard Medical School. About Ascentage Pharma Ascentage Pharma (6855.HK) is a global, integrated biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily in malignancies. On October 28, 2019, Ascentage Pharma was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code 6855.HK. The company has built a rich pipeline of innovative drug candidates that includes novel, highly potent Bcl-2 and dual Bcl-2/Bcl-xL inhibitors, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation TKIs. Ascentage Pharma is also the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators. The company has conducted more than 40 clinical trials in the US, Australia, Europe, and China, including 13 registrational studies (completed/ ongoing/planned). Olverembatinib, the company's first lead asset developed for the treatment of drug-resistant chronic myeloid leukemia (CML) and the company's first approved product in China, has been granted Priority Review Designations and Breakthrough Therapy Designations by the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA). To date, the drug had been included into the China National Reimbursement Drug List (NRDL). Furthermore, olverembatinib has been granted Orphan Drug Designations (ODDs) and a Fast Track Designation (FTD) by the US FDA, and an Orphan Designation by the EMA of the EU. To date, Ascentage Pharma has obtained a total of 16 ODDs from the US FDA and 1 Orphan Designation from the EMA of the EU for 4 of the company's investigational drug candidates. Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies such as Takeda, AstraZeneca, Merck, Pfizer and Innovent; and research and development relationships with leading research institutions such as Dana-Farber Cancer Institute, Mayo Clinic, MD Anderson Cancer Center, National Cancer Institute and the University of Michigan. The company has built a talented team with a wealth of global experience in the discovery and development of innovative drugs and fully functional commercial manufacturing and Sales & Marketing teams. One pivotal aim of Ascentage Pharma is to continuously strengthen its R&D capabilities and accelerate its clinical development programs, in order to fulfil its mission of addressing unmet clinical needs in China and around the world for the benefit of more patients. Forward-Looking Statements The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, Ascentage Pharma undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events, or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions and expectations or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions and expectations may alter in light of future development.
美國舊金山和中國蘇州2024年11月25日 /美通社/ -- 信達生物制藥集團（香港聯交所股票代碼：01801），一家致力於研發、生產和銷售腫瘤、自身免疫、代謝及心血管、眼科等重大疾病領域創新藥物的生物制藥公司，今日宣布，將在2024年歐洲腫瘤內科學會亞洲年會（ESMO Asia）上公布近10項臨床數據，含2項口頭報告，其中包括IBI343（創新TOPO1i CLDN18.2 ADC）治療胰腺癌的I期更新數據。ESMO Asia年會將於當地時間2024年12月6日-8日在新加坡舉辦。 詳細摘要信息如下： 口頭報告 摘要標題：抗Claudin18.2 (CLDN18.2) ADC藥物IBI343治療晚期胰腺導管腺癌 (PDAC): I期研究數據更新摘要編號: 132MO展示形式：Mini Oral展示時間：2024年12月7日, 09:50-09:55講者：張劍 教授，復旦大學附屬腫瘤醫院 摘要標題：mFOLFOX6+貝伐珠單抗+信迪利單抗 (PD-1抗體) 治療局部晚期MSS型結直腸癌：一項前瞻性、單臂、開放標簽II期研究（BASKET II）摘要編號：74MO展示形式：Mini Oral展示時間：2024年12月7日, 10:20-10:25 講者：黃俊 教授， 中山大學附屬第六醫院 壁報展示 摘要標題： 信迪利單抗聯合安羅替尼一線治療晚期腸癌 (APICAL-CRC)：一項開放標簽、單臂、II期研究摘要編號: 75P展示形式：壁報展示時間：2024年12月7日, 17:50-18:45講者：王湛 教授，上海長征醫院 摘要標題：肝動脈灌注化療（HAIC）聯合信迪利單抗和多納非尼作為不可切除肝內膽管癌一線治療的一項單臂、多中心、II期研究（CHANCE 2203）摘要編號：137P展示形式：壁報展示時間：2024年12月7日, 17:50-18:45講者：滕皋軍 教授，東南大學附屬中大醫院 摘要標題：FOLFOX-HAIC聯合信迪利單抗及貝伐珠單抗治療晚期肝細胞癌：一項單臂II期研究摘要編號：207P展示形式：壁報展示時間：2024年12月7日, 17:50-18:45講者：梁斌/王子卓 教授，華中科技大學同濟醫學院附屬協和醫院 摘要標題：肝動脈灌注化療（HAIC）聯合信迪利單抗和貝伐珠單抗用於晚期肝細胞癌患者治療的II期研究的更新結果摘要編號：214P展示形式：壁報展示時間：2024年12月7日, 17:50-18:45講者：張海斌 教授，上海東方肝膽外科醫院 中文標題: 信迪利單抗聯合安羅替尼vs. 免疫聯合化療治療圍手術期NSCLC：II期臨床研究摘要編號：599P展示形式：壁報展示時間：2024年12月7日, 17:50-18:45講者：儲天晴 教授，上海交通大學附屬胸科醫院 方案發表（TiP） 摘要標題： IBI310（抗CTLA-4抗體）聯合信迪利單抗作為可切除的MSI-H/dMMR結腸癌新輔助治療的一項隨機、對照、多中心的3期研究：正在進行中摘要編號：119TiP展示形式：壁報展示時間：2024年12月7日, 17:50-18:45講者：徐瑞華 教授，中山大學腫瘤防治中心 摘要標題: 信迪利單抗聯合化療及冷凍消融一線治療晚期非鱗狀非小細胞肺癌的療效和安全性摘要編號：722TiP展示形式：壁報展示時間：2024年12月7日, 17:50-18:45講者：高志強 教授，上海交通大學附屬胸科醫院 信達生物制藥集團高級副總裁周輝博士表示：「很高興在本次ESMO Asia大會上持續更新我們多個突破性臨床數據，尤其在全球難治癌種胰腺癌上，信達生物創新TOPO1i CLDN18.2 ADC IBI343，在早期少量人群初步療效信號的基礎上，擴大入組後依然看到了令人鼓舞的療效信號和良好的安全性。IBI343以其獨特的抗體端Fc沉默設計，穩定的linker，強活性extecan的payload，成為目前在PDAC治療方面進度最為領先的CLDN18.2 ADC分子。作為少數擁有『IO+ADC』技術平台和充沛管線儲備的生物制藥企業，信達生物將在癌症治療領域持續取得突破，致力於為醫生和患者提供更創新、有效和安全的治療手段及方案。」 關於信達生物 「始於信，達於行」，開發出老百姓用得起的高質量生物藥，是信達生物的使命和目標。信達生物成立於2011年，致力於研發、生產和銷售腫瘤、自身免疫、代謝、眼科等重大疾病領域的創新藥物，讓我們的工作惠及更多的生命。公司已有11個產品獲得批准上市，它們分別是信迪利單抗注射液（達伯舒®），貝伐珠單抗注射液（達攸同®），阿達木單抗注射液（蘇立信®），利妥昔單抗注射液（達伯華®），佩米替尼片（達伯坦®），奧雷巴替尼片（耐立克®）， 雷莫西尤單抗注射液（希冉擇®），塞普替尼膠囊（睿妥®），伊基奧侖賽注射液（福可蘇®），托萊西單抗注射液（信必樂®）和氟澤雷塞片（達伯特®）。目前，同時還有5個品種在NMPA審評中，3個新藥分子進入III期或關鍵性臨床研究，另外還有17個新藥品種已進入臨床研究。 公司已與禮來、羅氏、賽諾菲、Adimab、Incyte和MD Anderson 癌症中心等國際合作方達成30多項戰略合作。信達生物在不斷自研創新藥物、謀求自身發展的同時，秉承經濟建設以人民為中心的發展思想。多年來，始終心懷科學善念，堅守「以患者為中心」，心系患者並關注患者家庭，積極履行社會責任。公司陸續發起、參與了多項藥品公益援助項目，讓越來越多的患者能夠得益於生命科學的進步，買得到、用得起高質量的生物藥。截至目前，信達生物患者援助項目已惠及17余萬普通患者，藥物捐贈總價值34億元人民幣。信達生物希望和大家一起努力，提高中國生物制藥產業的發展水平，以滿足百姓用藥可及性和人民對生命健康美好願望的追求。 詳情請訪問公司網站：www.innoventbio.com或公司領英賬號www.linkedin.com/company/innovent-biologics/。 聲明：1.信達生物不推薦未獲批的藥品/適應症的使用。 2.雷莫西尤單抗注射液（希冉擇®）和塞普替尼膠囊（睿妥®）由禮來公司研發 前瞻性聲明 本新聞稿所發布的信息中可能會包含某些前瞻性表述。這些表述本質上具有相當風險和不確定性。在使用「預期」、「相信」、「預測」、「期望」、「打算」及其他類似詞語進行表述時，凡與本公司有關的，目的均是要指明其屬前瞻性表述。本公司並無義務不斷地更新這些預測性陳述。 這些前瞻性表述乃基於本公司管理層在做出表述時對未來事務的現有看法、假設、期望、估計、預測和理解。這些表述並非對未來發展的保證，會受到風險、不確性及其他因素的影響，有些乃超出本公司的控制范圍，難以預計。因此，受我們的業務、競爭環境、政治、經濟、法律和社會情況的未來變化及發展的影響，實際結果可能會與前瞻性表述所含資料有較大差別。
SINGAPORE, Nov. 25, 2024 /PRNewswire/ -- In just a few months, Novo AI's advanced solution has elevated APRIL International's performance across Thailand, Vietnam, Hong Kong, and Singapore, achieving more than three fold increase in efficiency and setting new benchmarks in private medical insurance. What was once a slow, costly process is now faster, more profitable, and delivers happier customers. Here's what happened. Pressing Challenges Undermining the Profitability of the Insurance Sector As a leading provider in the private medical insurance sector, APRIL International faces the ongoing challenge of managing vast volumes of complex medical claims. The high influx of non-standard documents requires extensive manpower to interpret and validate unstructured data, contributing to inefficiencies and high operational costs. Additionally, regional fraud and abuse levels range between 15%-35% from country to country, making it crucial for a company like APRIL International to identify a solution that captures fraud and abuse at scale, enhances efficiency and bolsters profitability. Old Problems Require New Solutions Facing a growing challenge, APRIL International was looking for a solution aimed at eliminating critical operational inefficiencies. One of their top priorities was to streamline document ingestion and management for healthcare claims, enabling real-time detection of inconsistencies across claims, providers and practitioner data. Crucially, this solution needed unwavering accuracy across 100% of claims and rapid deployment. The answer came from Novo AI. Their advanced solution generated a 230% boost in productivity and a 400% lift in efficiency for APRIL International. Tasks that once took 10 days now require only 2, with the system surpassing human accuracy in processing not only digital data, but also handwriting and stamps. Novo AI's CEO highlights, "Our solution delivers high accuracy claim-handling from day one and can adapt to specific business requirements without retraining. We streamline claim processing and fraud detection independently of policy writing, resulting in faster claim management. A faster claim process means happier customers for APRIL International, and in return, for Novo AI as well." APRIL International's CEO remarks: "Insurance involves processing vast amounts of data daily. Novo AI has allowed us to significantly accelerate our claims processing and detect fraud and abuse, enabling us to reduce unnecessary expenses and improve loss ratios across the region. We're excited by further developments who will help us optimize further for an improved customer experience and profitability." APRIL Asia Regional CEO Romain Di Meglio with Novo AI Co-founder & Chief Strategy Officer Julien Condamines This success marks a pivotal innovation in insurance, setting new industry standards. In its early stages of widespread adoption, Novo AI is already gearing up to deliver even more groundbreaking GenAI solutions. For more info: partnerships@heynovo.ai
A12 藝術空間
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
